Parkinson's disease

News

Illustration of the thought processes in the brain

FDA gives speedy review to Bayer's Parkinson's stem cell the...

Bayer subsidiary BlueRock Therapeutics has been granted a fast-track review by the FDA for DA01, its stem cell-based therapy for Parkinson's disease which is currently in early-stage clinic

News

Ipsen tries again in Parkinson's disease with $363m IRLAB de...

French drugmaker Ipsen has made another foray into the Parkinson's disease category, licensing rights to an oral dopamine D3 receptor antagonist from Sweden's IRLAB for $28 million upfront.

News

Close Up Of Senior Man Suffering With Parkinsons Diesease

Bayer's two-pronged cell/gene therapy assault on Parkinson's...

Bayer subsidiary BlueRock Therapeutics has dosed the first Parkinson's disease patient in a phase 1 trial of its cell-based therapy DA01, which aims to replenish the neurons lost in people

News

Cambridge Sleep Sciences’ device is trialled in Parkinson’s

Sleep disturbances are a common feature for people with Parkinson’s disease, and a device developed to help people with insomnia is now being trialled to see if it can improve their sleep q

News

AI drug discovery firm Valence joins Parkinson’s disease pus...

Canada’s Valence Discovery has joined a University of Montreal-led project to try to find new drugs to treat the involuntary movement complications that can accompany treatments for Parkins

Views & Analysis